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AltitudeAbstract Global variation in heart failure (HF) prevalence and mortality rates is evident and mul-
tiple factors have been hypothesised to explain such non-random distribution. The author hypoth-
esised that this non-random HF distribution could be attributed, in part, to individual variation in
the level of erythropoietin (EPO), a hormone and a possible cardioprotectant. Such individual EPO
variation can be explained by hypoxia resulting from regional differences in geographic elevation.
This hypothesis was justiﬁed using results from various animal-based and clinical studies. In addi-
tion, data from the population-based Healthcare Cost and Utilization Project was used. The global
distribution of HF can be explained, in part, by the geographic landscape. Prospective studies based
on the author’s hypothesis may provide new treatment opportunities for such an important health
issue as HF. In addition, this hypothesis may demonstrate new insights into the mechanism of HF.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. Introduction
Epidemiology of heart failure and the existence of ‘‘heart failure
belt’’
Heart failure (HF) is the leading cause of mortality worldwide
[1,2]. It is considered to be the new cardiovascular ‘epidemic’
of the 21st century. In the US only, it has been estimated that
HF contributes to approximately 250000 deaths annually and
more than 800000 Americans are hospitalised for HF each
year [1,2]. The number of hospital discharges associated with
HF in the US continues to increase and it is estimated thatrythropoietin; CI, conﬁdence inter
niversity of Medical Sciences. Pub
h/
/j.jmhi.2012.08.002nearly 5 million Americans are currently diagnosed with HF
[1,2]. The number of new cases of HF occurring annually in
the US is estimated to range between 400000 and 700000
though ﬁrm estimates of the magnitude of HF are currently
lacking [1,2]. HF is the leading cause of death and hospitalisa-
tion in individuals 65 years and older and this condition is
associated with a grim long-term prognosis [1,2].
Estimates of the magnitude of HF vary widely depending
on the source of data from which estimates are derived includ-
ing death certiﬁcates, hospital records or the results of general
population surveys [3,4]. Not surprisingly that, it is a challenge
to make a good comparison of the global data on HF.val; CDC, Centers for Disease Control
lished by Elsevier Ltd.Open access under CC BY-NC-ND license. 
Table 1 Global cities and capitals located at high altitudes
[13].
Country or state Capital Elevation (in meters)
Bolivia Sucre 2783
Ecuador Quito 2763
Colombia Bogota 2619
Eritrea Asmara 2363
Ethiopia Addis Ababa 2362
Mexico Ciudad de Mexico 2216
New Mexico Santa Fe 2152
Wyoming Cheyenne 1856
Colorado Denver 1613
Nevada Carson City 1462
Utah Salt Lake City 1308
Montana Helena 1262
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evident. For instance, research evidence suggests the existence
of what is called the ‘heart failure belt’ in the US where several
states in the southeastern part of the US were found to have a
substantially higher rates of HF [5]. These results were ob-
tained using large population-based data from Centers for Dis-
ease Control (CDC). Further, age-adjusted rates for HF were
obtained and International Statistical Classiﬁcation of Dis-
eases and Related Health Problems ninth edition (ICD-9)
codes were used to estimate HF mortality [5]. The 2000 US
census data were also used to examine death rates per
100000 individuals [5]. The total HF mortality rate was 31.0/
100000 and this rate was nearly 70% higher than the US na-
tional HF mortality rate [5]. No speciﬁc causation or hypoth-
esis was suggested by the study authors as a primary
explanation of such a striking difference and both blacks and
whites had similar HF mortality variation across the states [5].
Previously the author hypothesized that erythropoietin
(EPO) may explain, in part, a variation in stroke mortality
rates in the US also called ‘‘stroke belt’’ phenomenon [6].
Although this hypothesis was based on numerous results of
animal-based experiments and basic studies, no population-
based research was conducted. More importantly, HF and
stroke differ substantially in their anatomic and physiologic
peculiarities, diagnostic and treatment procedures as well as
epidemiologic pattern.
HF, EPO and geographic altitude
Human kidney and fetal liver produce EPO to protect against
potential damage by hypoxia. Higher concentrations of EPO
were recorded in human serum as early as 1.5 h after exposure
to hypoxia [7]. Although the release of EPO can be regulated
by some factors such as blood loss or genetics, hypoxaemia
is of crucial importance [8–10].
Former research evidence suggests that modest decrease in
oxygen supply can result in moderate production of EPO while
hypoxia caused by high altitudes may result in a substantial, al-
most twofold, renal EPO production when the altitude reaches
3000 m [7]. Interestingly, those who were exposed to various de-
grees of altitude ranging from 1780 to 2800 m responded with
similar production of EPO [11]. A stable production of EPO
at 1780 m above the sea level was recorded in this study [11].
The landscape of the Earth varies from country to country
with altitudes inhabited by humans ranging substantially. Some
examples of cities and capitals located at high altitudes are pro-
vided in Table 1. In the US, some mountain states such as Colo-
rado or Utah have mean altitude equal to 2100 and 1900 m,
respectively, while lowland states such as Florida or New Jersey
have mean altitude lower than 91 m [12]. However, HF is a com-
plexdiseaseandnumerous factors shouldbe considered to explain
its non-random distribution. For example, the relationship be-
tween HF mortality, altitude and EPO could be inﬂuenced by
other important factors such as age, access to health care and re-
lated co-morbidities. If successful, prospective studies based on
this hypothesis should consider a complex interplay of various
factors related to HF non-random geographic distribution.
The hypothesis
Geographic landscape in most countries of the world varies,
which results in the fact that some regions have higher andsome regions have lower altitudes. High altitudes cause hypox-
ia and the human kidney releases EPO as the part of the phys-
iologic response to hypoxia. The author hypothesises that this
non-random HF distribution can be attributed to individual
variation in the level of EPO, a hormone and a possible cardio-
protectant. Such individual EPO variation can be explained by
hypoxia resulting from regional differences in geographic ele-
vation. Therefore, based on the author’s hypothesis, global dis-
tribution of HF can be explained, in part, by the geographic
landscape.
Methods
Evaluation of the hypothesis, part 1: EPO is a cardiovascular
protectant
Administration of EPO in HF patients is often associated with
the treatment of anaemia. The latter contributes substantially
to more frequent hospitalisations and deaths among patients
with HF. In addition to treating anaemia, some other impor-
tant clinical signs such as improved left-ventricular functions
or better adaptation to physical exercise were observed in pa-
tients with congestive HF receiving darbepoetin-alpha or re-
combinant EPO therapy [13–16].
In general, patients with congestive HF are noticed to have
a higher concentration of EPO as compared to healthy sub-
jects. Some studies suggest that EPO could predict morbidity
and mortality in those patients [17,18]. In the author’s opinion,
congestive HF results in such a profound tissue hypoxia that it
possibly triggers EPO production which, in turn, improves
erythropoiesis and certain cardiac protection functions. For
those who live in the mountain regions, such a mechanism is
turned on by ‘natural’ hypoxia due to differences in geographic
altitude.
Other possible mechanisms include stabilisation of certain
cytokines such as interleukin-6 (IL-6) or IL-1b in the myocar-
dium [19]. Animal models of HF showed diminished cardiac
ﬁbrosis following EPO administration [19]. In addition, some
studies suggested that EPO could play a beneﬁcial role against
myocardial injury [20]. When EPO was administered during
acute coronary injury, a substantially smaller infarct size as
well as general improvement in left-ventricular function was
observed [21–23]. Moreover, a mouse that lacked the EPO
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onary artery blockage [24]. Finally, those patients diagnosed
with the ﬁrst episode of myocardial infarction and who had
higher levels of EPO were shown to present smaller infarct size
evidenced by lower creatinine kinase levels [25].
Stimulation of angiogenesis by EPO signaling modulates is
another important cardioprotective mechanism [26,27]. Some
animal-based studies have shown that EPO may induce myo-
cardial neoangiogenesis following myocardial infarction
[28,29]. Administration of EPO was shown to result in a signif-
icant growth of new cardiac capillaries regulated by increase in
bone marrow-derived EPCs in the endothelium [30]. Stimula-
tion of angiogenesis by EPO was also shown in mice and chick-
en embryos [31,32], as well as in studies investigating the
mechanism of wound healing [33].
Other beneﬁcial properties of EPO are also important to
consider. Research evidence suggests that free iron may inten-
sify oxidative stress as well as contribute to the severity of lung
injuries [34,35]. One of the solutions is to chelate iron by var-
ious regimens such as deferasirox, which may be useful in pa-
tients with various hyperoxic states [34,35]. Alternatively, EPO
may diminish the level of free iron by using it for further eryth-
ropoiesis. Therefore, EPO administration could be potentially
beneﬁcial in patients with acute or decompensated HF.
Evaluation of the hypothesis, part 2: population-based evidence
Based on the hypothesis, one should expect that the states in
the ‘lowland’ such as Louisiana or Alabama should have high-
er HF rates as compared to the states from the mountain re-
gions such as Colorado or Utah. To evaluate the hypothesis
further, some population-based data were analysed as follows.
Inpatient data have been derived from the Healthcare Cost
and Utilization Project Nationwide Inpatient Sample. The
Nationwide Inpatient Sample (NIS) contains a national all-
payer data set with 7.45 million uniform hospital discharge ab-
stracts for all inpatient stays in 2001. The detailed description
of the data is available from http://www.hcup-us.ahrq.gov/db/
nation/nis/Overview_of_NIS_2001_25Jul03.pdf. The impor-
tant feature of theNIS is availability of International Classiﬁca-
tion of Diseases, Ninth Revision, ClinicalModiﬁcation (ICD-9-
CM) diagnosis codes. The other variable of interest is the state
location and the NIS contains data collected from 33 states.
HFwas identiﬁed based on ICD-9-CMdiagnostic codes (428.x).
A convenience random sample of 5%was created. Cases have
been examined by total number of admissions and by HF admis-
sions. Out of 33 states available for analysis, ﬁve states with high
mean altitude (Arizona (AZ, 1200 m), California (CA, 880 m),
Colorado (CO, 1900 m), Oregon (OR, 1000 m) and Utah (UT,
1900 m)) and ﬁve states with low mean altitude (Connecticut
(CT, 150 m), Florida (FL, 30 m), Maryland (MD, 110 m), New
Jersey (NJ, 76 m), South Carolina (SC, 110 m)) were selected
[12]. The proportion of HF admissions to all admissions was cal-
culated for each selected state. Data analyses were conducted by
using Statistical Package for Social Sciences (SPSS) forWindows
(version 12.0; SPSS, Chicago, IL, USA).the US state
Figure 1 Heart failure admissions in the ‘‘mountain’’ and in the
‘‘lowland’’ US states. Abbreviations: MD: Maryland; NJ: New
Jersey; FL: Florida; SC: South Carolina; CT: Connecticut; OR:
Oregon; CO: Colorado; CA: California; AZ: Arizona; UT: Utah.Results
Results are summarised in Fig. 1. The ﬁgure shows that the
proportion of HF admissions to all admissions in the US stateswith low mean altitude (painted black) is substantially higher
than such a proportion in the states with high mean altitude
(painted grey). For example, the proportion of HF admissions
to all admissions in Maryland is nearly twofold bigger than
such a proportion in Utah (0.123 vs. 0.064, respectively). Inter-
estingly, the calculated proportions do not necessarily corre-
late with the altitude. For example, Colorado has a
substantially higher mean altitude as compared to California
(1900 vs. 880 m, respectively) yet the proportion of HF admis-
sions to all admissions is not substantially different (0.076 vs.
0.071, respectively) [12]. This suggests, on the one hand, the
inﬂuence of various complex factors other than EPO. In addi-
tion, readers should bear in mind that places with extremely
high altitude are usually not densely populated and there are
few US cities located there. One of the examples is Santa Fe,
the capital of New Mexico, which has a mean altitude of
approximately 2200 m [12].
Discussion
HF is a complex syndrome of profound clinical and public
health importance. This condition is characterised by signs
and symptoms of a decompensated state resulting in impaired
myocardial function, often representing the end stage of sev-
eral cardiac diseases. As HF is a clinical syndrome, and not
a distinct disease entity, there are many challenges to the sys-
tematic study of this condition. Complicating the study of
HF is that there are multiple contributory factors involved in
its development, and individual levels of EPO could be one
of them.
While limited contemporary information is available about
the descriptive epidemiology of HF, particularly from the more
generalisable perspective of a population-based investigation,
HF is associatedwith signiﬁcantmorbidity andmortalityworld-
wide. Estimates of the magnitude of HF vary widely depending
on the source of data fromwhich estimates are derived including
death certiﬁcates, hospital records or the results of general pop-
ulation surveys [3,4]. Not surprisingly, it is a challenge tomake a
good comparison of the global data on HF. Here is an example
of two locations in Brazil, Sao Paulo located at 800 m andBahia
located at 14 m.Data provided by theWorldHeart Failure Soci-
ety show that the proportion of all deaths attributed to HF in
Sao Paulo is substantially smaller than in Bahia (0.01972 vs.
0.03150) [36]. Nevertheless, the impact of the hypothesis could
be particularly beneﬁcial for countries with substantial variation
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for treatment of HF can be established.
To evaluate the hypothesis, prospective studies should in-
clude a detailed examination of factors related to HF as well
as a prospective design. Study subjects should be identiﬁed
from various geographical altitudes to investigate individual
levels of EPO in relation to HF rates. Finally, future studies
based on this hypothesis should consider a complex interplay
of various factors related to HF mortality rates.
Other research avenues should be explored. Because of the
numerous non-haematopoietic effects of EPO, similar associa-
tions between geographic altitude and some other diseases
such as stroke should be examined. For example, higher stroke
mortality rates are reported in the southeast of the US partic-
ularly along the coastline [37–39]. The so-called ‘stroke belt’
phenomenon refers to several states including Alabama,
Arkansas, Georgia, Indiana, Kentucky, Louisiana, Missis-
sippi, North Carolina, South Carolina, Tennessee and Vir-
ginia. In the same time, lower rates have been observed in
the mountain region [37–39]. Most of the population from
the ‘stroke belt’ states live below the US mean altitude value
while, in contrast, most of the population of the states with
low stroke mortality rates such as Nebraska, Arizona, New
Mexico, Wyoming and Colorado live above the US mean alti-
tude value [6]. It is possible that the non-random stroke distri-
bution is also related to individual differences of EPO [6].
Conclusion
In conclusion, based on the author’s hypothesis, the global dis-
tribution of HF can be explained, in part, by the geographic
landscape. If successful, prospective studies based on this
hypothesis may provide new treatment opportunities for such
an important health issue as HF. More importantly, future
studies based on this theory may illustrate new insights into
the mechanism of HF as well as other diseases that have a
non-random geographic distribution.
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Global variation in heart failure (HF) prevalence
and mortality rates is evident and multiple factors
have been hypothesised to explain such a non-ran-
dom distribution. A classic example is the so-called
‘heart failure belt’ phenomenon in the US.
The suggested hypothesis may explain, in part, such
a non-random global variation of HF. If successful,
prospective studies based on this hypothesis may
provide new treatment opportunities as well as new
insights into the mechanism of HF.
To evaluate the author’s hypothesis, prospective
studies should include a detailed examination of fac-
tors related to HF as well as a prospective design.
Study subjects should be identiﬁed from various geo-
graphical altitudes to investigate individual levels of
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